Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Increase in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Increase in Short Interest
biOasis Technologies, Inc operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 19,800 shares, a growth of 18.6% from the March 31st total of 16,700 shares. Based on an average daily trading volume, of 3,000 shares, the days-to-cover ratio is presently 6.6 days.
4月份，Bioasis Technologies Inc.（OTCMKTS: BIOAF — 獲取評級）的空頭利息大幅增長。截至4月15日，空頭利息總額爲19,800股，較3月31日的16,700股增長了18.6％。根據3,000股的平均每日交易量，目前的回報天數爲6.6天。
Bioasis Technologies Stock Performance
Bioasis科技股票表現
Shares of Bioasis Technologies stock opened at $0.01 on Friday. The stock has a market capitalization of $1.03 million, a price-to-earnings ratio of -0.43 and a beta of 0.48. Bioasis Technologies has a 1-year low of $0.01 and a 1-year high of $0.21. The firm's 50-day moving average price is $0.02 and its two-hundred day moving average price is $0.05.
Bioasis Technologies股票週五開盤價爲0.01美元。該股票的市值爲103萬美元，市盈率爲-0.43，beta值爲0.48。Bioasis Technologies的1年低點爲0.01美元，1年高點爲0.21美元。該公司的50天移動平均價格爲0.02美元，其200天移動平均線價格爲0.05美元。
Bioasis Technologies Company Profile
Bioasis科技公司簡介
(Get Rating)
（獲取評級）
biOasis Technologies, Inc operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier.
BioAsis Technologies, Inc是一家生物製藥公司。它專注於神經系統疾病和疾病（例如腦癌、神經退行性疾病和代謝性疾病）的診斷和治療的研究和開發。其產品包括作爲其專有載體的Transcend計劃、p97和穿越血腦屏障的成像劑。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- 免費獲取 StockNews.com 關於 Bioasis Technologies（BIOAF）的研究報告的
- MarketBeat 週迴顧 — 4 月 24 日 — 4 月 28 日
- 如何投資今年最熱門的雜貨股
- Array Technologies將太陽耀斑帶入
- 在利率上升之前投資的最佳銀行股
- 如何投資農田：7 種簡單方法
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收Bioasis科技的新聞和收視率 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Bioasis Technologies及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
